Multicenter prospective cohort study of adverse events associated with biliary endoscopic retrograde cholangiopancreatography: Incidence of adverse events and preventive measures for post-endoscopic retrograde cholangiopancreatography pancreatitis

Koichi Fujita, Shujiro Yazumi, Hisakazu Matsumoto, Masanori Asada, Hiroko Nebiki, Kazuya Matsumoto, Toru Maruo, Mamoru Takenaka, Takeshi Tomoda, Takumi Onoyama, Akira Kurita, Toshiharu Ueki, Toshiro Katayama, Takashi Kawamura, Hirofumi Kawamoto, Bilio-pancreatic Study Group of West Japan, Koichi Fujita, Shujiro Yazumi, Hisakazu Matsumoto, Masanori Asada, Hiroko Nebiki, Kazuya Matsumoto, Toru Maruo, Mamoru Takenaka, Takeshi Tomoda, Takumi Onoyama, Akira Kurita, Toshiharu Ueki, Toshiro Katayama, Takashi Kawamura, Hirofumi Kawamoto, Bilio-pancreatic Study Group of West Japan

Abstract

Objectives: The reported incidence of adverse events (AEs) in endoscopic retrograde cholangiopancreatography (ERCP) varies between 2.5% and 14%. The aim of this study was to evaluate the incidence and severity of AEs in biliary ERCP and to specify the risk factors and preventive measures for post-ERCP pancreatitis (PEP).

Methods: Patients with biliary disease with intact papilla were prospectively enrolled at 36 hospitals between April 2017 and March 2018. The primary outcomes were the incidence and severity of AEs.

Results: A total of 16,032 ERCP procedures were performed at the 36 hospitals during the study period and 3739 patients were enrolled. The overall incidence of AEs was 10.1% and ERCP-related mortality was 0.08%. PEP developed in 258 cases (6.9%), bleeding in 33 (0.9%), instrumental AEs in 17 (0.5%), infections in 37 (1.0%), cardiovascular AEs in eight (0.2%), pulmonary AEs in eight (0.2%), drug reaction AE in one (0.03%), pain in 15 (0.4%), and other AEs in 15 (0.4%). Multivariable analysis showed significant risk factors for PEP were: female of younger age, pancreatic guidewire-assisted biliary cannulation, temporary guidewire insertion into the pancreatic duct, total procedure time >60 min, and post-ERCP administration of non-steroidal anti-inflammatory drugs. Effective preventive measures were prophylactic pancreatic stenting (PPS) and epinephrine spraying onto the papilla.

Conclusions: In patients with intact papilla who underwent biliary ERCP, the incidence of AEs was 10.1% and the mortality was 0.08%. PPS and epinephrine spraying may prevent PEP.

Registration: This study was registered in the University Hospital Medical Information Network (UMIN000024820).

Keywords: cholangiopancreatography; endoscopic retrograde; pancreatitis.

Conflict of interest statement

Authors declare no conflict of interest for this article.

© 2021 The Authors. Digestive Endoscopy published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.

References

    1. Andriulli A, Loperfido S, Napolitano G et al. Incidence rates of post‐ERCP complications: A systematic survey of prospective studies. Am J Gastroenterol 2007; 102: 1781–8.
    1. Kochar B, Akshintala VS, Afghani E et al. Incidence, severity, and mortality of post‐ERCP pancreatitis: A systematic review by using randomized, controlled trials. Gastrointest Endosc 2015; 81: 143–9.e9.
    1. Halttunen J, Meisner S, Aabakken L et al. Difficult cannulation as defined by a prospective study of the Scandinavian Association for Digestive Endoscopy (SADE) in 907 ERCPs. Scand J Gastroenterol 2014; 49: 752–8.
    1. Testoni PA, Mariani A, Aabakken L et al. Papillary cannulation and sphincterotomy techniques at ERCP: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy 2016; 48: 657–83.
    1. Freeman ML, Nelson DB, Sherman S et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335: 909–18.
    1. Chandrasekhara V, Khashab MA, Muthusamy VR et al. Adverse events associated with ERCP. Gastrointest Endosc 2017; 85: 32–47.
    1. Fujimoto K, Fujishiro M, Kato M et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc 2014; 26: 1–14.
    1. Kato M, Uedo N, Hokimoto S et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment: 2017 appendix on anticoagulants including direct oral anticoagulants. Dig Endosc 2018; 30: 433–40.
    1. Cotton PB, Eisen GM, Aabakken L et al. A lexicon for endoscopic adverse events: Report of an ASGE workshop. Gastrointest Endosc 2010; 71: 446–54.
    1. Cotton PB, Lehman G, Vennes J et al. Endoscopic sphincterotomy complications and their management: An attempt at consensus. Gastrointest Endosc 1991; 37: 383–93.
    1. Sofuni A, Maguchi H, Mukai T et al. Endoscopic pancreatic duct stents reduce the incidence of post‐endoscopic retrograde cholangiopancreatography pancreatitis in high‐risk patients. Clin Gastroenterol Hepatol 2011; 9: 851–8.
    1. Kiriyama S, Takada T, Strasberg SM et al. TG13 guidelines for diagnosis and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci 2013; 20: 24–34.
    1. Testoni PA, Mariani A, Giussani A et al. Risk factors for post‐ERCP pancreatitis in high‐ and low‐volume centers and among expert and non‐expert operators: A prospective multicenter study. Am J Gastroenterol 2010; 105: 1753–61.
    1. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49: 1373–9.
    1. Dumonceau JM, Kapral C, Aabakken L et al. ERCP‐related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2020; 52: 127–49.
    1. Matsushita M, Takakuwa H, Shimeno N, Uchida K, Nishio A, Okazaki K. Epinephrine sprayed on the papilla for prevention of post‐ERCP pancreatitis. J Gastroenterol 2009; 44: 71–5.
    1. Xu LH, Qian JB, Gu LG et al. Prevention of post‐endoscopic retrograde cholangiopancreatography pancreatitis by epinephrine sprayed on the papilla. J Gastroenterol Hepatol 2011; 26: 1139–44.
    1. Akshintala VS, Hutfless SM, Colantuoni E et al. Systematic review with network meta‐analysis: Pharmacological prophylaxis against post‐ERCP pancreatitis. Aliment Pharmacol Ther 2013; 38: 1325–37.
    1. Katoh T, Kawashima K, Fukuba N et al. Low‐dose rectal diclofenac does not prevent post‐ERCP pancreatitis in low‐ or high‐risk patients. J Gastroenterol Hepatol 2020; 35: 1247–53.
    1. Tomoda T, Kato H, Miyamoto K et al. Efficacy of low dose rectal diclofenac for preventing post‐endoscopic retrograde cholangiopancreatography pancreatitis: Propensity score‐matched analysis. Dig Endosc 2021; 33: 656–62.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren